DOMA Nominates New Directors to Revitalize Pacira
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 11 2026
0mins
Should l Buy PCRX?
Source: Newsfilter
- Stock Price Decline: Pacira's stock has plummeted 56% over the last decade and 68% over the past five years, indicating a significant loss of investor confidence in management and raising concerns about the company's future viability.
- Call for Management Change: DOMA asserts that CEO Frank Lee should be replaced immediately, advocating for the board to appoint an interim CEO and initiate a formal sale process to address the board's severe deficiencies in financial oversight and management control.
- Executive Compensation Issues: Over the past two years, executive compensation at Pacira has approached 7% of the firm's market capitalization, while earnings per share have failed to materialize, highlighting a troubling disconnect between management pay and company performance that has exacerbated shareholder dissatisfaction.
- Need for Strategic Transformation: DOMA believes that Pacira's EXPAREL drug holds significant value, but management's poor strategic execution has undermined its market potential, necessitating a board overhaul to reassess decisions and strategies to maximize shareholder interests.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PCRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PCRX
Wall Street analysts forecast PCRX stock price to rise
6 Analyst Rating
4 Buy
1 Hold
1 Sell
Moderate Buy
Current: 22.880
Low
23.00
Averages
30.33
High
38.00
Current: 22.880
Low
23.00
Averages
30.33
High
38.00
About PCRX
Pacira BioSciences, Inc. is the holding company for its subsidiary, Pacira Pharmaceuticals, Inc. The Company has three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain, and iovera, a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The Company is also advancing the development of PCRX-201, a locally administered gene therapy with the potential to treat largely prevalent diseases like osteoarthritis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PACIRA BIOSCIENCES: BARCLAYS LOWERS TARGET PRICE FROM $27 TO $25
- Barclays Adjusts Price Target: Barclays has reduced its price target for a specific stock from $27 to $25.
- Market Implications: This adjustment may reflect changing market conditions or company performance expectations.
See More
DOMA Nominates New Directors for Pacira Amid Management Concerns
- Leadership Change Needed: DOMA Perpetual has nominated three candidates to Pacira BioSciences' board due to concerns over management and financial controls, emphasizing that the current leadership has failed to address stock price declines and earnings misses effectively.
- Inadequate Financial Controls: Holding approximately 7.1% of Pacira's shares, DOMA pointed out that under CEO Frank Lee, the stock has fallen by 30%, while executive compensation has soared, highlighting serious governance issues within the company.
- Restoring Shareholder Confidence: DOMA believes a leadership change is necessary to restore shareholder confidence and has suggested that the board consider selling the company and halt future acquisitions, arguing that the current management has not met performance targets.
- Market Performance Analysis: Although Pacira's stock has increased by 3.58% over the past year and shows some short-term strength, its Benzinga Edge score indicates a mixed outlook, suggesting that the company still faces challenges in the market.
See More
DOMA Calls for Replacement of Pacira Management
- Stock Price Decline: Pacira's stock has fallen 56% over the last decade and 68% over the last five years, indicating a significant lack of trust in management and severely undermining investor confidence in the company's future prospects.
- Poor Management Performance: Under CEO Frank Lee's leadership, the stock has dropped 30%, with the company failing to achieve profitability for two consecutive years while continuously lowering guidance, highlighting severe missteps in strategic execution and financial oversight.
- Board Oversight Failure: DOMA's nomination of three director candidates with extensive experience in strategic capital allocation and risk management aims to enhance the board's financial controls and management oversight, ensuring that shareholder interests are adequately represented.
- Unjustified Executive Compensation: Pacira's management compensation approaches 7% of the firm's market capitalization, and over the past two years, the CEO's pay has exceeded the total earnings per share distributed to all shareholders, reflecting significant mismanagement and excessive spending.
See More
DOMA Nominates New Directors to Revitalize Pacira
- Stock Price Decline: Pacira's stock has plummeted 56% over the last decade and 68% over the past five years, indicating a significant loss of investor confidence in management and raising concerns about the company's future viability.
- Call for Management Change: DOMA asserts that CEO Frank Lee should be replaced immediately, advocating for the board to appoint an interim CEO and initiate a formal sale process to address the board's severe deficiencies in financial oversight and management control.
- Executive Compensation Issues: Over the past two years, executive compensation at Pacira has approached 7% of the firm's market capitalization, while earnings per share have failed to materialize, highlighting a troubling disconnect between management pay and company performance that has exacerbated shareholder dissatisfaction.
- Need for Strategic Transformation: DOMA believes that Pacira's EXPAREL drug holds significant value, but management's poor strategic execution has undermined its market potential, necessitating a board overhaul to reassess decisions and strategies to maximize shareholder interests.
See More
Pacira BioSciences Q4 2025 Earnings Call Insights
- Significant Revenue Growth: Pacira BioSciences reported $726 million in revenue for 2025, helping 2.5 million patients, demonstrating strong market demand and the company's leadership in pain management, with a goal to assist 3 million patients by 2030, further solidifying market share.
- Enhanced Patent Protection: A patent settlement with Fresenius extends EXPAREL's exclusivity through 2039, increasing the patent estate to 21 patents, ensuring revenue stability and competitive advantage for the company in the long term.
- Strategic Partnership Expansion: The collaboration with LG Chem accelerates Pacira's commercialization efforts in Asia-Pacific markets, with revenue expected to begin in 2027, enhancing the company's global market presence and influence.
- Optimistic Future Outlook: The CFO projected total revenue for 2026 to be between $745 million and $770 million, with EXPAREL sales expected to be between $600 million and $620 million, reflecting the company's confidence in future growth while maintaining a non-GAAP gross margin of up to 79%.
See More
Pacira Biosciences Issues 2026 Revenue Guidance Below Consensus
- Lowered Revenue Guidance: Pacira Biosciences projects 2026 revenue between $745 million and $770 million, falling short of the market consensus of $792.23 million, indicating potential challenges in future growth that may impact investor confidence.
- Poor Financial Performance: The company reported a non-GAAP EPS of $0.57 for Q4 2025, significantly down from $0.96 in the same period last year, reflecting a decline in profitability that could further pressure the stock price.
- Weak Sales Growth: Sales of Exparel increased only 5% year-over-year to $155.8 million, while Zilretta's sales remained flat at $33 million, indicating competitive pressures that could affect Pacira's future market share.
- Deteriorating Cash Position: As of 2025, Pacira's cash and cash equivalents stood at approximately $238.4 million, a significant drop from $484.6 million on December 31, 2024, potentially limiting the company's ability to invest in R&D and market expansion.
See More
PACIRA BIOSCIENCES: BARCLAYS LOWERS TARGET PRICE FROM $27 TO $25
- Barclays Adjusts Price Target: Barclays has reduced its price target for a specific stock from $27 to $25.
- Market Implications: This adjustment may reflect changing market conditions or company performance expectations.
See More
DOMA Nominates New Directors for Pacira Amid Management Concerns
- Leadership Change Needed: DOMA Perpetual has nominated three candidates to Pacira BioSciences' board due to concerns over management and financial controls, emphasizing that the current leadership has failed to address stock price declines and earnings misses effectively.
- Inadequate Financial Controls: Holding approximately 7.1% of Pacira's shares, DOMA pointed out that under CEO Frank Lee, the stock has fallen by 30%, while executive compensation has soared, highlighting serious governance issues within the company.
- Restoring Shareholder Confidence: DOMA believes a leadership change is necessary to restore shareholder confidence and has suggested that the board consider selling the company and halt future acquisitions, arguing that the current management has not met performance targets.
- Market Performance Analysis: Although Pacira's stock has increased by 3.58% over the past year and shows some short-term strength, its Benzinga Edge score indicates a mixed outlook, suggesting that the company still faces challenges in the market.
See More
DOMA Calls for Replacement of Pacira Management
- Stock Price Decline: Pacira's stock has fallen 56% over the last decade and 68% over the last five years, indicating a significant lack of trust in management and severely undermining investor confidence in the company's future prospects.
- Poor Management Performance: Under CEO Frank Lee's leadership, the stock has dropped 30%, with the company failing to achieve profitability for two consecutive years while continuously lowering guidance, highlighting severe missteps in strategic execution and financial oversight.
- Board Oversight Failure: DOMA's nomination of three director candidates with extensive experience in strategic capital allocation and risk management aims to enhance the board's financial controls and management oversight, ensuring that shareholder interests are adequately represented.
- Unjustified Executive Compensation: Pacira's management compensation approaches 7% of the firm's market capitalization, and over the past two years, the CEO's pay has exceeded the total earnings per share distributed to all shareholders, reflecting significant mismanagement and excessive spending.
See More
DOMA Nominates New Directors to Revitalize Pacira
- Stock Price Decline: Pacira's stock has plummeted 56% over the last decade and 68% over the past five years, indicating a significant loss of investor confidence in management and raising concerns about the company's future viability.
- Call for Management Change: DOMA asserts that CEO Frank Lee should be replaced immediately, advocating for the board to appoint an interim CEO and initiate a formal sale process to address the board's severe deficiencies in financial oversight and management control.
- Executive Compensation Issues: Over the past two years, executive compensation at Pacira has approached 7% of the firm's market capitalization, while earnings per share have failed to materialize, highlighting a troubling disconnect between management pay and company performance that has exacerbated shareholder dissatisfaction.
- Need for Strategic Transformation: DOMA believes that Pacira's EXPAREL drug holds significant value, but management's poor strategic execution has undermined its market potential, necessitating a board overhaul to reassess decisions and strategies to maximize shareholder interests.
See More
Pacira BioSciences Q4 2025 Earnings Call Insights
- Significant Revenue Growth: Pacira BioSciences reported $726 million in revenue for 2025, helping 2.5 million patients, demonstrating strong market demand and the company's leadership in pain management, with a goal to assist 3 million patients by 2030, further solidifying market share.
- Enhanced Patent Protection: A patent settlement with Fresenius extends EXPAREL's exclusivity through 2039, increasing the patent estate to 21 patents, ensuring revenue stability and competitive advantage for the company in the long term.
- Strategic Partnership Expansion: The collaboration with LG Chem accelerates Pacira's commercialization efforts in Asia-Pacific markets, with revenue expected to begin in 2027, enhancing the company's global market presence and influence.
- Optimistic Future Outlook: The CFO projected total revenue for 2026 to be between $745 million and $770 million, with EXPAREL sales expected to be between $600 million and $620 million, reflecting the company's confidence in future growth while maintaining a non-GAAP gross margin of up to 79%.
See More
Pacira Biosciences Issues 2026 Revenue Guidance Below Consensus
- Lowered Revenue Guidance: Pacira Biosciences projects 2026 revenue between $745 million and $770 million, falling short of the market consensus of $792.23 million, indicating potential challenges in future growth that may impact investor confidence.
- Poor Financial Performance: The company reported a non-GAAP EPS of $0.57 for Q4 2025, significantly down from $0.96 in the same period last year, reflecting a decline in profitability that could further pressure the stock price.
- Weak Sales Growth: Sales of Exparel increased only 5% year-over-year to $155.8 million, while Zilretta's sales remained flat at $33 million, indicating competitive pressures that could affect Pacira's future market share.
- Deteriorating Cash Position: As of 2025, Pacira's cash and cash equivalents stood at approximately $238.4 million, a significant drop from $484.6 million on December 31, 2024, potentially limiting the company's ability to invest in R&D and market expansion.
See More
